Showing: 1 - 9 of 9 RESULTS
Briefing Mind Medicine MindMed Psychedelics Technology

MindMed Acquires HealthMode For $41.6 Million

MindMed (NEO: MMED) this morning announced that it will be acquiring that of HealthMode in a largely stock-based transaction. HealthMode is a digital medicine and therapeutics startup focused on the use of artificial intelligence to improve the precision and speed of clinical research and patient monitoring. The acquisition will reportedly see the company strengthen its …

Briefing Pharmather Psychedelics Technology

PharmaTher To Develop Digital Therapeutics Platform Focused On Psychedelic Therapies

Pharmather Inc (CSE: PHRM) this morning announced that it has amended its sponsored research agreement with that of the University Health Network. The revised agreement, which was originally just focused on the development of panaceAI, will now also include the development of a digital therapeutics platform to combine with potential psychedelic therapies. The digital therapeutics …

Briefing Mind Cure Health Psychedelics Technology

Mind Cure Enters LOI To Acquire Ephiphany360 Digital Therapeutics Platform

Mind Cure Health (CSE: MCUR) is getting into the digital therapeutics space. The company announced this morning that it entered into a non-binding letter of intent late last week to acquire Ephiphany360. Ephiphany360 is a digital, cloud-based platform focused on treating mental health. The platform is designed to co-ordinate care between health practitioners, such as …

Briefing Psychedelics Revive Therapeutics Technology

Revive Therapeutics To Conduct Phase 1 Clinical Trials For Psilocybin

Revive Therapeutics (CSE: RVV) is driving forward with its psilocybin studies. The company announced this morning that it has entered into a clinical trial agreement with the University of Wisconsin to conduct a clinical study focused on the use of psilocybin in adults that suffer from methamphetamine use disorder. Under the terms of the agreement, …

Briefing Psychedelics Revive Therapeutics Technology

Revive Therapeutics Receives First Prototype of Orally Dissolvable Psilocybin Film Strips

Revive Therapeutics (CSE: RVV) this morning announced that it has received the first set of orally dissolvable thin film strips, which will be utilized to deliver psilocybin and additional psychedelic-derived medicine to a patient. The film strips were received in connection with its sponsored research partnership agreement that Revive currently has in place with the …

Briefing Coronavirus Psychedelics Revive Therapeutics Technology

Revive Announces Timeline For Phase 3 Studies, Sees Beneficial Psilocybin Developments

Revive Therapeutics (CSE: RVV) this morning announced that on the heels of receiving FDA approval for phase 3 clinical trials of Bucillamine in the treatment of COVID-19, it currently intends to begin the clinical trials in September. The company is currently in the process of finalizing agreements and aligning resources to conduct the trials. Currently, …

Briefing News Psychedelics Revive Therapeutics Technology

Revive Therapeutics Sees Research Partnership On Psilocybin Expanded

Revive Therapeutics (CSE: RVV) has expanded its sponsored research partnership agreement with that of the University of Wisconsin-Madison related to the study of psilocybin. The partnership will see Revive and the University evaluate novel formulations and a phase 1 clinical study for the therapeutic application of psilocybin for an addiction use disorder. Development work conducted …

Briefing Psychedelics Revive Therapeutics Technology

The Deep Dive Compiles Company Profile on Revive Therapeutics

The Deep Dive has assembled a company profile for that of Revive Therapeutics (CSE: RVV), a life sciences company focused on three verticals within the biotech space. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take …

Briefing News Psychedelics Revive Therapeutics Technology

Revive Therapeutics To Investigate Novel Oral Dosage Forms Of Psilocybin

Revive Therapeutics (CSE: RVV) has provided an update to the market in regards to its psilocybin-based pharmaceutical program. Revive intends to utilize its patent-pending psilocybin formulations and its exclusive licensed drug delivery technology to investigate novel oral dosage forms of psilocybin, such as in the form of tablets or thin films like breath strips. It …